

Maureen J Lage

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9556319/publications.pdf>

Version: 2024-02-01

48
papers

1,365
citations

361413

20
h-index

345221

36
g-index

49
all docs

49
docs citations

49
times ranked

1746
citing authors

#	ARTICLE	IF	CITATIONS
1	Comorbidities and Costs of Adult Patients Diagnosed with Attention-Deficit Hyperactivity Disorder. <i>Pharmacoeconomics</i> , 2005, 23, 93-102.	3.3	189
2	The cost of treating anxiety: the medical and demographic correlates that impact total medical costs. <i>Depression and Anxiety</i> , 2005, 21, 178-184.	4.1	157
3	The cost of treating skeletal-related events in patients with prostate cancer. <i>American Journal of Managed Care</i> , 2008, 14, 317-22.	1.1	100
4	The association between diabetes related medical costs and glycemic control: a retrospective analysis. <i>Cost Effectiveness and Resource Allocation</i> , 2006, 4, 1.	1.5	96
5	Medical and productivity costs of anxiety disorders: Case control study. <i>Depression and Anxiety</i> , 2004, 19, 112-120.	4.1	80
6	The relationship between antipsychotic medication adherence and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective study. <i>Annals of General Psychiatry</i> , 2009, 8, 7.	2.7	56
7	Effect of Methylphenidate Formulation for Attention Deficit Hyperactivity Disorder on Patterns and Outcomes of Treatment. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2004, 14, 575-581.	1.3	45
8	Early Discontinuation and Restart of Insulin in the Treatment of Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2014, 5, 225-242.	2.5	45
9	Olanzapine versus Risperidone in the Treatment of Schizophrenia. <i>Pharmacoeconomics</i> , 2003, 21, 683-697.	3.3	43
10	Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1299-1304.	4.4	36
11	The relationship between HbA1c reduction and healthcare costs among patients with type 2 diabetes: evidence from a U.S. claims database. <i>Current Medical Research and Opinion</i> , 2020, 36, 1441-1447.	1.9	34
12	Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data. <i>BMC Health Services Research</i> , 2014, 14, 286.	2.2	32
13	Outcomes of Medicaid Beneficiaries With Schizophrenia Receiving Clozapine Only or Antipsychotic Combinations. <i>Psychiatric Services</i> , 2015, 66, 127-133.	2.0	30
14	Trends in the prescription of antidiabetic medications in France: Evidence from primary care physicians. <i>Advances in Therapy</i> , 2007, 24, 803-813.	2.9	28
15	Costs and Resource Use of Mild Persistent Asthma Patients Initiated on Controller Therapy. <i>Journal of Asthma</i> , 2008, 45, 293-299.	1.7	25
16	Medication adherence and improved outcomes among patients with type 2 diabetes. <i>American Journal of Managed Care</i> , 2017, 23, e208-e214.	1.1	25
17	The association between adherence to levothyroxine and economic and clinical outcomes in patients with hypothyroidism in the US. <i>Journal of Medical Economics</i> , 2018, 21, 912-919.	2.1	24
18	Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study. <i>Journal of Medical Economics</i> , 2014, 17, 21-31.	2.1	23

#	ARTICLE	IF	CITATIONS
19	Effect of methylphenidate formulation on treatment patterns and use of emergency room services. American Journal of Health-System Pharmacy, 2006, 63, 317-322.	1.0	21
20	Adherence to Basal Insulin Therapy Among People with Type 2 Diabetes: A Retrospective Cohort Study of Costs and Patient Outcomes. Diabetes Therapy, 2018, 9, 1099-1111.	2.5	21
21	Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis. Advances in Therapy, 2009, 26, 552-562.	2.9	20
22	Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population. Diabetes Therapy, 2018, 9, 637-650.	2.5	19
23	Trends in HbA1c and Body Mass Index Among Individuals with Type 2 Diabetes: Evidence from a US Database 2012-2019. Diabetes Therapy, 2021, 12, 2077-2087.	2.5	19
24	Obesity and glycemic control among people with type 2 diabetes in the United States: A retrospective cohort study using insurance claims data. Journal of Diabetes and Its Complications, 2021, 35, 107975.	2.3	17
25	A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine. Applied Health Economics and Health Policy, 2009, 7, 245-254.	2.1	16
26	Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts. Journal of Medical Economics, 2010, 13, 464-471.	2.1	14
27	The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study. Journal of Medical Economics, 2013, 16, 1231-1237.	2.1	13
28	The Association Between Sustained HbA1c Control and Long-Term Complications Among Individuals with Type 2 Diabetes: A Retrospective Study. Advances in Therapy, 2022, 39, 2208-2221.	2.9	13
29	Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy. Advances in Therapy, 2009, 26, 217-229.	2.9	12
30	Glatiramer acetate versus interferon beta-1a for subcutaneous administration: Comparison of outcomes among multiple sclerosis patients. Advances in Therapy, 2008, 25, 658-673.	2.9	11
31	Patterns of blood glucose monitoring in relation to glycemic control among patients with type 2 diabetes in the UK. Journal of Diabetes and Its Complications, 2007, 21, 181-186.	2.3	10
32	The association between the severity of chronic kidney disease and medical costs among patients with type 2 diabetes. Journal of Medical Economics, 2019, 22, 447-454.	2.1	9
33	Healthcare outcomes for patients with type 2 diabetes with and without comorbid obesity. Journal of Diabetes and Its Complications, 2020, 34, 107730.	2.3	9
34	Healthcare costs in postmenopausal women with hormone-positive metastatic breast cancer. Journal of Medical Economics, 2010, 13, 691-697.	2.1	8
35	Medication Use, Service Utilization, and Medical Costs Associated With New Episodes of Bipolar Disorder. Primary Care Companion To the Journal of Clinical Psychiatry, 2007, 09, 280-286.	0.6	8
36	Insulin Dosing and Outcomes Among Commercially Insured Patients With Type 2 Diabetes in the United States. Clinical Therapeutics, 2015, 37, 2297-2308.e1.	2.5	7

#	ARTICLE	IF	CITATIONS
37	Trends in U.S. Insulin Use and Glucose Monitoring for People with Diabetes: 2009-2018. Journal of Diabetes Science and Technology, 2021, , 193229682110282.	2.2	7
38	Chronic Medication Burden and Complexity for US Patients with Type 2 Diabetes Treated with Glucose-Lowering Agents. Diabetes Therapy, 2020, 11, 1513-1525.	2.5	7
39	Outcomes and costs of patients with persistent asthma treated with beclomethasone dipropionate hydrofluoroalkane or fluticasone propionate. Advances in Therapy, 2009, 26, 762-775.	2.9	6
40	The Association Between Adherence to Insulin Therapy and Health Care Costs for Adults with Type 2 Diabetes: Evidence from a U.S. Retrospective Claims Database. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1081-1089.	0.9	6
41	Obesity and the use of insulin: a study of patients with type 2 diabetes in the UK. Journal of Diabetes and Its Complications, 2008, 22, 235-240.	2.3	5
42	Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting. Clinical Therapeutics, 2018, 40, 1396-1407.	2.5	5
43	The Association Between HbA1c and 1-Year Diabetes-Related Medical Costs: A Retrospective Claims Database Analysis. Diabetes Therapy, 2022, 13, 367-377.	2.5	5
44	The Relationship Between Timing of Initiation on a Glucagon-like Peptide-1 Receptor Agonist and Glycosylated Hemoglobin Values Among Patients With Type 2 Diabetes. Clinical Therapeutics, 2020, 42, 1812-1817.e2.	2.5	3
45	The Association Between Switching from Synthroid® and Clinical Outcomes: US Evidence from a Retrospective Database Analysis. Advances in Therapy, 2021, 38, 337-349.	2.9	2
46	Comment on generalizability of GLP-1 RA CVOTs in US T2D population. American Journal of Managed Care, 2019, 25, 170-171.	1.1	2
47	Glycemic control and the first use of oral antidiabetic agents among patients with type 2 diabetes mellitus. Current Medical Research and Opinion, 2013, 29, 1587-1597.	1.9	1
48	Time to Failure on Oral Glucose-Lowering Agents for Patients with Type 2 Diabetes: A Retrospective Cohort Study. Diabetes Therapy, 2021, 12, 1463-1474.	2.5	1